BioStock: FDA approves Abliva’s IND-application for KL1333
For Swedish biotech Abliva and its lead project KL1333, 2021 has been a year marked by steady advancement towards a registrational phase II/III study. The project has now reached one of its most significant milestones to date, through an approval from the US Food and Drug Administration (FDA) for the company´s Investigational New Drug (IND)-application. This means that the phase II/III study can be initiated, and the company expects to start patient recruitment during 2022.
Read the article about Abliva at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/